SonALAsense

Berkeley, CA

SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors. It utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells. Their use of an MRI-guided focused ultrasound device with ALA is a truedrug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well-elucidated mechanism of action (creation of reactive oxygen species). The company was founded in 2019 and is based in Berkeley, California.